KEYNOTE-146 Results at ESMO 2020

Abstract No : Abstract #710P

Indication : Renal cell carcinoma

Intervention : Lenvatinib + Pembrolizumab

Company : Merck & Co.

Technology : PD-1/MultiTKI Inhibitor


For the 104 pts enrolled, median duration of follow-up for OS was 12.3 months, 65% of pts had prior anti-PD-1/PD-L1 andanti-VEGF therapy in combination or sequentially, and 37% of pts had prior nivolumab + ipilimumab. At week 24, 53/104 ptsachieved a confirmed partial response for an ORR of 51% by investigator assessment (Table). Median duration of response(DOR) was 12.2 months and median progression-free survival (PFS) was 11.7 months by irRECIST. The most commontreatment-related adverse events (TRAEs) were fatigue, diarrhea, proteinuria , dysphonia ,hypertension , nausea, and stomatitis.


LEN + PEMBRO demonstrated promising antitumor activity in mccRCC after ICI therapy. No new safety signals were detected